Earnings ·
Ovid Therapeutics reports Q3 net loss of $20.8M, cash balance of $161.4M
OVIDOvid Therapeutics Inc.
Ovid Therapeutics reported a third-quarter 2026 net loss of $20.8 million, or $0.10 per share, compared to a $12.2 million loss in the prior-year period. Total operating expenses rose to $22.4 million from $12.7 million, driven by increased research and development costs for OV329 and OV4071 programs. The company ended the quarter with $161.4 million in cash, equivalents, and marketable securities, providing a financial runway into 2029. Pipeline updates include ongoing Phase 2 enrollment for OV329 in focal epilepsy and Phase 1 studies for KCC2 activator OV4071, with key data readouts expected in early 2027.